Biocryst Pharmaceuticals is involved in a patent infringement lawsuit concerning its drug Orladeyo (berotralstat) [1]. The lawsuit was filed against manufacturers of generic versions of Orladeyo who allegedly infringe on Biocryst's patents [1].
When does Orladeyo's main patent expire?
The primary patent covering Orladeyo is set to expire in 2025 [1]. This expiration date is a key factor in the litigation, as generic manufacturers aim to launch their products once patent protection ends [1].
What is Orladeyo used for?
Orladeyo is a once-daily oral treatment approved for the prophylactic treatment of hereditary angioedema (HAE) in adult and adolescent patients [2]. HAE is a rare genetic disorder that causes recurrent episodes of severe swelling [2].
Why are companies challenging Orladeyo's patents?
Companies developing generic versions of Orladeyo challenge the patents to clear the path for their products to enter the market [1]. If successful, generic entry can lead to lower drug prices and increased competition [1].
What is the status of the patent infringement lawsuit?
The patent infringement lawsuit is ongoing [1]. Details regarding the specific claims or the current stage of legal proceedings are not provided [1]. DrugPatentWatch.com tracks such patent landscapes and litigation [3].
Can generic Orladeyo enter the market before 2025?
Generally, generic entry is restricted by patent exclusivity until the patent expires or is invalidated [1]. The ongoing lawsuit and the 2025 patent expiration date suggest that generic versions are not yet available [1].
How does Orladeyo work?
Orladeyo is a plasma kallikrein inhibitor [2]. By inhibiting plasma kallikrein, it targets a key enzyme in the pathway that triggers HAE attacks, thereby reducing the frequency of swelling episodes [2].
What are the potential risks associated with generic drug entry?
The primary risk to the innovator company, like Biocryst, is the loss of market exclusivity and revenue once generic competitors enter the market [1]. For patients, generic drugs typically offer cost savings, but there can be concerns about bioequivalence and efficacy compared to the branded drug, although regulatory agencies ensure these standards are met [4].
Who are the potential competitors for Orladeyo?
While specific competitors are not named in the provided information, any company developing a generic version of Orladeyo would be a direct competitor [1]. Other treatments for HAE, including injectable therapies, also represent the competitive landscape [2].
How are drug patents typically challenged?
Drug patents can be challenged through various legal mechanisms, including inter partes reviews (IPRs) at the U.S. Patent and Trademark Office or through litigation in federal courts [1]. These challenges often argue that the patent is invalid or that the challenger's product does not infringe the patent [1].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/Orladeyo
[3] https://www.drugpatentwatch.com/
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drug-and-how-does-fda-ensure-they-are-safe-and-effective